albendazole has been researched along with Brain Diseases in 134 studies
Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effectiveness of two regimens of albendazole therapy for neurocysticercosis." | 9.08 | Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. ( Altamirano, J; Boero, J; Cuba, JM; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Horton, J; Martinez, M; Rios-Saavedra, N; Verastegui, M, 1997) |
| "Albendazole is considered the drug of choice for neurocysticercosis." | 9.08 | Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. ( Bonato, PS; Lanchote, VL; Marques, MP; Takayanagui, OM, 1997) |
| "The purpose of this study was to determine the therapeutic efficacy of albendazole and praziquantel administration in the treatment of neurocysticercosis of the fourth ventricle." | 9.08 | Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. ( Correa, D; García, L; García-Torres, E; Madrazo, I; Proaño, JV, 1997) |
| "We treated 11 patients with a persistent (> 3 months), solitary small cysticercus granuloma and seizures with albendazole in a daily dose of 15 mg/kg body weight for 14 days." | 9.07 | Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures. ( Rajshekhar, V, 1993) |
| "One hundred consecutive patients presenting with symptoms and signs of neurocysticercosis, confirmed by neuroimaging techniques were randomly assigned to treatment with either praziquantel 50 mg/kg/day for 15 days or albendazole 15 mg/kg/day for 30 days." | 9.07 | Clinical evaluation of albendazole and praziquantel in the treatment of cerebral cysticercosis. ( Cruz, I; Cruz, M; Horton, J, 1991) |
| "Praziquantel and albendazole have been recently described as effective drugs for treatment of intraparenchymal brain cysticercosis." | 9.07 | Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. ( Jardim, E; Takayanagui, OM, 1992) |
| "Albendazole (ABZ) is effective in the treatment of neurocysticercosis." | 7.71 | Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ( Bonato, PS; Dreossi, SA; Lanchote, VL; Takayanagui, OM, 2002) |
| "Albendazole, a newer paracidal drug, seems to be more effective and less expensive than some other drugs in use for the treatment of neurocysticercosis." | 7.69 | Cerebral and subcutaneous cysticercosis treated with albendazole. ( Cilliers, J; Jordaan, HF; Schmidt, DK; Schneider, JW, 1995) |
| "Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days." | 7.69 | Severe forms of neurocysticercosis: treatment with albendazole. ( Agapejev, S; Da Silva, MD; Ueda, AK, 1996) |
| "The authors report a case of neurocysticercosis treated with Albendazole (methyl-5-propyl-thio-2-benzimidazilcarbamate)." | 7.69 | Neurocysticercosis treated with albendazole long term follow-up of a case. ( Maddalena, G; Nozzoli, C; Passarella, B, 1995) |
| "Albendazole has been used successfully in the treatment of cerebral cysticercosis for several years." | 7.69 | Neurocysticercosis: optimal dose treatment with albendazole. ( Carrasco, F; Cruz, I; Cruz, ME; Horton, J, 1995) |
| "Ten cases of cerebral cysticercosis, treated with 2-week course of albendazole, were reported." | 7.68 | Treatment of neurocysticercosis with a two week course of albendazole. ( Chotmongkol, V, 1993) |
| "Albendazole or praziquantel were measured in plasma and cerebrospinal fluid (CSF) in 29 patients with neurocysticercosis." | 7.68 | Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. ( Hurtado, M; Jung, H; Medina, MT; Sanchez, M; Sotelo, J, 1990) |
| "Albendazole pharmacokinetics were studied in eight patients who were receiving albendazole in doses of 15 mg/kg per day for 8 days as treatment of brain cysticercosis." | 7.68 | Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. ( Hurtado, M; Jung, H; Medina, MT; Sanchez, M; Sotelo, J, 1992) |
| "Praziquantel and albendazole have been recently described as effective drugs for treating cysticercosis of the brain." | 7.67 | Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. ( Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Albendazole is now used for therapy of neurocysticercosis; however, duration of treatment has usually been empirically determined." | 7.67 | Short course of albendazole therapy for neurocysticercosis. ( Del Brutto, OH; Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Seven patients with chronic parenchymal brain cysticercosis were treated with albendazole for one month at daily doses of 15 mg/kg of body weight." | 7.67 | Albendazole therapy for neurocysticercosis. ( Escobedo, F; Penagos, P; Rodriguez, J; Sotelo, J, 1987) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 6.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| "Seizures were present in 94." | 6.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "Albendazole was administered orally in a dose of 15 mg/kg bodyweight/day for 30 days without prophylactic steroids." | 6.67 | Albendazole therapy for neurocysticercosis. ( Dhamija, RM; Roy, AK; Sanchetee, PC; Venkataraman, S, 1994) |
| "To evaluate two different dosage regimens for albendazole (7." | 6.67 | Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis. ( González-Esquivel, D; Jung, H; Sánchez, M; Sotelo, J; Suástegui, R, 1993) |
| " In the current study, the efficacy of MSCs alone or combined with albendazole was evaluated against chronic brain insults induced by Toxocara canis infection in an experimental mouse model." | 5.56 | Mesenchymal stem cells combined with albendazole as a novel therapeutic approach for experimental neurotoxocariasis. ( Afifi, AF; Beshay, EVN; El-Refai, SA; Elbadry, AA; Sadek, GS; Shalan, FH, 2020) |
| "Treatment with praziquantel resulted in the regression of only some of the cysts." | 5.28 | [Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis]. ( Belec, L; Cohen, L; Pierrot-Deseilligny, C; Sanson, M; Signoret, JL, 1992) |
| "We conducted a double-blind, placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days (60 patients) or two placebos (60 patients)." | 5.11 | A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. ( Del Brutto, OH; Evans, CA; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Martinez, SM; Moulton, LH; Pretell, EJ, 2004) |
| "In children, intracranial granuloma diagnosed on computerized tomography (CT) scan and presenting with seizures as the sole manifestation has traditionally been treated with antitubercular (ATB) therapy or albendazole (Alb) in addition to antiepileptic drugs (AED)." | 5.09 | Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas? ( Kanhere, S; Mehta, R; Naik, N; Rajadhyaksha, S; Shah, KN, 1999) |
| "Randomized clinical trial of treatment of patients with newly identified active neurocysticercosis with oral prednisolone alone (27 patients), praziquantel with prednisolone (54 patients), or albendazole with prednisolone (57 patients)." | 5.08 | Is the course of neurocysticercosis modified by treatment with antihelminthic agents? ( Carpio, A; Flores, C; Hauser, WA; León, P; Santillán, F, 1995) |
| "The purpose of this study was to determine the therapeutic efficacy of albendazole and praziquantel administration in the treatment of neurocysticercosis of the fourth ventricle." | 5.08 | Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. ( Correa, D; García, L; García-Torres, E; Madrazo, I; Proaño, JV, 1997) |
| "To compare the effectiveness of two regimens of albendazole therapy for neurocysticercosis." | 5.08 | Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. ( Altamirano, J; Boero, J; Cuba, JM; Garcia, HH; Gilman, RH; Gonzalez, AE; Herrera, G; Horton, J; Martinez, M; Rios-Saavedra, N; Verastegui, M, 1997) |
| "Albendazole is considered the drug of choice for neurocysticercosis." | 5.08 | Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. ( Bonato, PS; Lanchote, VL; Marques, MP; Takayanagui, OM, 1997) |
| "One hundred consecutive patients presenting with symptoms and signs of neurocysticercosis, confirmed by neuroimaging techniques were randomly assigned to treatment with either praziquantel 50 mg/kg/day for 15 days or albendazole 15 mg/kg/day for 30 days." | 5.07 | Clinical evaluation of albendazole and praziquantel in the treatment of cerebral cysticercosis. ( Cruz, I; Cruz, M; Horton, J, 1991) |
| "We treated 11 patients with a persistent (> 3 months), solitary small cysticercus granuloma and seizures with albendazole in a daily dose of 15 mg/kg body weight for 14 days." | 5.07 | Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures. ( Rajshekhar, V, 1993) |
| "Praziquantel and albendazole have been recently described as effective drugs for treatment of intraparenchymal brain cysticercosis." | 5.07 | Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. ( Jardim, E; Takayanagui, OM, 1992) |
| "The efficacy of different regimens of therapy for parenchymal brain cysticercosis either with praziquantel (PZQ) or with albendazole (ALB) was compared in 114 patients." | 5.06 | Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. ( del Brutto, OH; Escobedo, F; Penagos, P; Rodriguez-Carbajal, J; Rubio-Donnadieu, F; Sotelo, J; Torres, B, 1990) |
| " A 32 yr old man on treatment with Albendazole for cerebral neurocysticercosis for 10 days presented with 3 days of painful uniocular blindness." | 3.76 | Monocular blindness during therapy for cerebral neurocysticercosis. ( Asole, D; Chawla, V; Lakkas, Y; Shrivastava, M; Sundar, U; Vaidy, M, 2010) |
| "Albendazole (ABZ) is effective in the treatment of neurocysticercosis." | 3.71 | Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ( Bonato, PS; Dreossi, SA; Lanchote, VL; Takayanagui, OM, 2002) |
| "Albendazole, a newer paracidal drug, seems to be more effective and less expensive than some other drugs in use for the treatment of neurocysticercosis." | 3.69 | Cerebral and subcutaneous cysticercosis treated with albendazole. ( Cilliers, J; Jordaan, HF; Schmidt, DK; Schneider, JW, 1995) |
| "The authors report a case of neurocysticercosis treated with Albendazole (methyl-5-propyl-thio-2-benzimidazilcarbamate)." | 3.69 | Neurocysticercosis treated with albendazole long term follow-up of a case. ( Maddalena, G; Nozzoli, C; Passarella, B, 1995) |
| "Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days." | 3.69 | Severe forms of neurocysticercosis: treatment with albendazole. ( Agapejev, S; Da Silva, MD; Ueda, AK, 1996) |
| "Albendazole has been used successfully in the treatment of cerebral cysticercosis for several years." | 3.69 | Neurocysticercosis: optimal dose treatment with albendazole. ( Carrasco, F; Cruz, I; Cruz, ME; Horton, J, 1995) |
| "Albendazole or praziquantel were measured in plasma and cerebrospinal fluid (CSF) in 29 patients with neurocysticercosis." | 3.68 | Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. ( Hurtado, M; Jung, H; Medina, MT; Sanchez, M; Sotelo, J, 1990) |
| "Albendazole is considered to be the drug of choice for treatment of parenchymal brain cysticercosis." | 3.68 | Albendazole therapy for giant subarachnoid cysticerci. ( Aguirre, R; Alarcón, TA; Del Brutto, OH; Díaz-Calderón, E; Sotelo, J, 1992) |
| "Ten cases of cerebral cysticercosis, treated with 2-week course of albendazole, were reported." | 3.68 | Treatment of neurocysticercosis with a two week course of albendazole. ( Chotmongkol, V, 1993) |
| "Albendazole pharmacokinetics were studied in eight patients who were receiving albendazole in doses of 15 mg/kg per day for 8 days as treatment of brain cysticercosis." | 3.68 | Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. ( Hurtado, M; Jung, H; Medina, MT; Sanchez, M; Sotelo, J, 1992) |
| "Albendazole is now used for therapy of neurocysticercosis; however, duration of treatment has usually been empirically determined." | 3.67 | Short course of albendazole therapy for neurocysticercosis. ( Del Brutto, OH; Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Praziquantel and albendazole have been recently described as effective drugs for treating cysticercosis of the brain." | 3.67 | Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. ( Escobedo, F; Penagos, P; Sotelo, J, 1988) |
| "Seven patients with chronic parenchymal brain cysticercosis were treated with albendazole for one month at daily doses of 15 mg/kg of body weight." | 3.67 | Albendazole therapy for neurocysticercosis. ( Escobedo, F; Penagos, P; Rodriguez, J; Sotelo, J, 1987) |
| "Neurocysticercosis is a parasitic infection of the central nervous system by the larval stage of the pork tapeworm and is a common cause of seizures and epilepsy in endemic areas." | 2.72 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Monk, EJM; Ranganathan, LN, 2021) |
| "Twenty-three patients had seizure recurrence while on antiepilepsy drugs: 36." | 2.71 | Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. ( Jain, V; Khandelwal, N; Singhi, P, 2004) |
| "Seizure recurrence was seen in three children each in both groups, after a mean interval of 6." | 2.70 | Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up. ( Baranwal, AK; Khandelwal, N; Singhi, PD; Singhi, SC, 2001) |
| "Seizures were present in 94." | 2.69 | Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. ( Khandelwal, N; Ray, M; Singhi, P; Singhi, S, 2000) |
| "To evaluate two different dosage regimens for albendazole (7." | 2.67 | Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis. ( González-Esquivel, D; Jung, H; Sánchez, M; Sotelo, J; Suástegui, R, 1993) |
| "Albendazole was administered orally in a dose of 15 mg/kg bodyweight/day for 30 days without prophylactic steroids." | 2.67 | Albendazole therapy for neurocysticercosis. ( Dhamija, RM; Roy, AK; Sanchetee, PC; Venkataraman, S, 1994) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| " The patient was started on albendazole (ABZ) at a daily dosage of 800 mg for 3 months." | 2.44 | Cerebral alveolar echinococcosis. A case report with MRI and review of the literature. ( Cerçi, A; Elmaci, I; Isik, N; Kalelioglu, M; Karabagli, P; Silav, G, 2007) |
| " Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours." | 2.40 | Pharmacokinetic optimisation of the treatment of neurocysticercosis. ( Jung, H; Sotelo, J, 1998) |
| "Multiple hydatid cysts of the brain are uncommon and may be either primary or secondary." | 2.40 | Multiple hydatid cysts of the brain: a case report and review of the literature. ( Güven, MB; Yilmaz, H; Yüceer, N, 1998) |
| "Treatment with praziquantel or albendazole has hastened the disappearance of the cysts on computed tomography and improved clinical symptoms." | 2.38 | Neurocysticercosis: neurologic, pathogenic, diagnostic and therapeutic aspects. ( Davis, LE; Kornfeld, M, 1991) |
| "When she presented with further seizures 6 months later, attempts to arrange neuroimaging and specialist assessment were unsuccessful owing to restrictions on routine healthcare services during the SARS-CoV-2 nationwide lockdown." | 1.62 | Hydatid brain cyst: A delayed diagnosis in a rural setting during COVID-19. ( Brink, AJ; Da Fonseca, SP; Enslin, JMN; Nuttall, J; Opperman, CJ; Tootla, HD, 2021) |
| " In the current study, the efficacy of MSCs alone or combined with albendazole was evaluated against chronic brain insults induced by Toxocara canis infection in an experimental mouse model." | 1.56 | Mesenchymal stem cells combined with albendazole as a novel therapeutic approach for experimental neurotoxocariasis. ( Afifi, AF; Beshay, EVN; El-Refai, SA; Elbadry, AA; Sadek, GS; Shalan, FH, 2020) |
| "Intracranial hydatid disease is relatively rare; the incidence is approximately 1%-2%." | 1.51 | Giant Primary Intracranial Hydatid Cyst in Child with Hemiparesis. ( Başkurt, O; Gök, H, 2019) |
| "We report a case of a hydatid cyst of the eyelid in a 12-year-old boy associated with cerebral involvement." | 1.43 | Swollen eyelid reveals multiple intracranial hydatid cysts associated with a palpebral cyst. ( Abboud, H; Ahbeddou, S; Ahmimech, J; Berraho, A; Boutarbouch, M; El Hassan, A; Tzili, N, 2016) |
| "Only one patient had spinal hydatidosis." | 1.39 | Primary intracranial and spinal hydatidosis: a retrospective study of 21 cases. ( Luo, DH; Luo, K; Wen, H; Zhang, TR, 2013) |
| "Cerebral hydatid disease is approximately 5% of alveolar hydatid cases and generally considered to be fatal." | 1.38 | Echinococcus alveolaris: presenting as a cerebral metastasis. ( Binici, DN; Kurt, A; Ozdemir, NG; Ozsoy, KM, 2012) |
| "Neurological examination revealed sixth nerve palsy and papilloedema." | 1.38 | [Two cases of rare cerebral hydatid cyst]. ( Işıkay, S; Ölmez, A; Yılmaz, K, 2012) |
| "Neurocysticercosis is the most common parasitic infection of the central nervous system." | 1.37 | Neurocysticercosis in Qatari patients: case reports. ( Imam, YZ; Kamel, H; Khan, FY; Shafaee, M, 2011) |
| "vogeli andE." | 1.36 | A medically treated multiple cerebral hydatid cyst disease. ( Altas, M; Aras, M; Davran, R; Evirgen, O; Serarslan, Y; Yilmaz, N, 2010) |
| "Association of nephrotic syndrome is described in pulmonary and hepatic hydatid cysts, but never reported in intracranial hydatidosis." | 1.36 | Primary extradural hydatid cyst associated with nephrotic syndrome in a pediatric patient. ( Brar, R; Khosla, VK; Sharma, T, 2010) |
| "Neurocysticercosis is the most common parasitic infestation of the central nervous system, which manifests commonly as acute-onset focal seizures." | 1.35 | Sudden-onset ptosis caused by midbrain neurocysticercosis in 2 children. ( Khandelwal, NK; Mahajan, V; Singhi, P, 2008) |
| "This case of microsporidiosis manifested as mutiple intracranial lesions separated in space and time, and neurological and radiological findings were improved with albendazole administration." | 1.35 | [Multiple intracerebral enhanced lesions strongly suspected to be microsporidiosis. A case report]. ( Kanamori, M; Kumabe, T; Okuyama, H; Tominaga, T; Watanabe, M, 2008) |
| "Neurocysticercosis is the most common parasitic disease of the central nervous system." | 1.35 | [Degenerating neurocysticercosis cysts: differential diagnosis with cerebral metastasis]. ( Bouvier, C; Coulibaly, B; Fuentes, S; Gautier, G; Ranque, S, 2008) |
| "Neurocysticercosis was easy to misdiagnose." | 1.35 | Clinical analysis of 52 cases of neurocysticercosis. ( Chaoshuang, L; Xiaohong, W; Zhanlian, H; Zhiliang, G; Zhixin, Z, 2008) |
| "Albendazole was administered to 192 patients; 93 patients had open surgical procedure and 99 patients underwent percutaneous procedure." | 1.33 | Our experience in eight cases with urinary hydatid disease: a series of 372 cases held in nine different clinics. ( Arslan, H; Ceylan, K; Güneş, M; Kösem, M; Köseoglu, B; Söylemez, O; Yalçinkaya, I; Yilmaz, Y, 2006) |
| "Cerebral involvement in hydatid disease occurs in 1-4% of cases." | 1.33 | Primary intracranial hydatid cyst in the interpeduncular cistern. ( Albayrak, L; Beskonakli, E; Solaroglu, I; Tun, K, 2005) |
| "Open heart surgery was performed and a hydatid cyst that involved the interatrial septum was enucleated." | 1.32 | The case of a cyst hydatid localized within the interatrial septum. ( Açikel, U; Algin, I; Erdal, CA; Itil, O; Karabay, O; Kilci, G; Onen, A; Sanli, A; Yildiz, F; Yilmaz, E, 2004) |
| "Isolated intracerebral manifestation of cystic echinococcosis is very rare." | 1.31 | [Isolated intracerebral cystic echinococcosis. Unusual presentation of a rare disease]. ( Böhmer, RH; Flügel, KA; Fuchs, HH; Lücking, MO; Nowak, DA; Schreiner, R, 2002) |
| "In Japan neurocysticercosis is a rare disease." | 1.31 | [A case of neurocysticercosis presenting as focal seizure]. ( Higuchi, H; Kobayashi, N; Okada, T; Sugiyama, M; Teramoto, A; Yabe, Y, 2000) |
| "Albendazole has been used in cases of multiple involvement, with controversial results." | 1.31 | Brain hydatidosis: report on 117 cases. ( Kallel, J; Khaldi, M; Khouja, N; Mohamed, S, 2000) |
| "Neurocysticercosis is an infection of the central nervous system with the pork tapeworm's cysticercus." | 1.30 | Neurocysticercosis in pregnancy: a case initially diagnosed as eclampsia. ( Iannucci, TA; Suarez, VR, 1999) |
| "Periventricular localization of hydatid cyst is very rarely seen." | 1.30 | Periventricular hydatid cyst. ( Gökalp, HZ; Yüceer, N, 1998) |
| "Standard treatment of cerebral alveolar hydatid disease consists of open brain surgery and systemic albendazole." | 1.30 | Gamma knife radiosurgery and albendazole for cerebral alveolar hydatid disease. ( Eustacchio, S; Pendl, G; Ranner, G; Reisinger, EC; Samonigg, H; Schmid, M, 1998) |
| "Treatment with albendazole was used in three cases without significant results." | 1.29 | Cerebral hydatid cyst in children. Experience of 27 cases. ( Carp, N; Ciurea, AV; Nuteanu, L; Vasilescu, G, 1995) |
| "Treatment with praziquantel resulted in the regression of only some of the cysts." | 1.28 | [Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis]. ( Belec, L; Cohen, L; Pierrot-Deseilligny, C; Sanson, M; Signoret, JL, 1992) |
| "After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder." | 1.28 | The course of seizures after treatment for cerebral cysticercosis. ( Sotelo, J; Vazquez, V, 1992) |
| "Albendazole was very well tolerated." | 1.27 | Albendazole treatment of multiple cerebral hydatid cysts: case report. ( Balkanski, G; Petkov, D; Todorov, T; Vutova, K, 1988) |
| "Albendazole was effective in the treatment of A." | 1.27 | Larvicidal effect of albendazole against Angiostrongylus cantonensis in mice. ( Chen, ER; Hwang, KP, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (6.72) | 18.7374 |
| 1990's | 71 (52.99) | 18.2507 |
| 2000's | 30 (22.39) | 29.6817 |
| 2010's | 21 (15.67) | 24.3611 |
| 2020's | 3 (2.24) | 2.80 |
| Authors | Studies |
|---|---|
| Opperman, CJ | 1 |
| Enslin, JMN | 1 |
| Nuttall, J | 1 |
| Brink, AJ | 1 |
| Da Fonseca, SP | 1 |
| Tootla, HD | 1 |
| Beshay, EVN | 1 |
| El-Refai, SA | 1 |
| Sadek, GS | 1 |
| Elbadry, AA | 1 |
| Shalan, FH | 1 |
| Afifi, AF | 1 |
| Monk, EJM | 1 |
| Abba, K | 3 |
| Ranganathan, LN | 3 |
| Villela, VA | 1 |
| Dixon, AM | 1 |
| Steele, R | 1 |
| Gök, H | 1 |
| Başkurt, O | 1 |
| Dhingra, D | 1 |
| Sethi, GR | 1 |
| Mantan, M | 1 |
| Darwazah, AK | 1 |
| Zaghari, M | 1 |
| Eida, M | 1 |
| Batrawy, M | 1 |
| Luo, K | 1 |
| Luo, DH | 1 |
| Zhang, TR | 1 |
| Wen, H | 1 |
| Sundaresan, S | 1 |
| Sanklecha, M | 1 |
| Tzili, N | 1 |
| Ahbeddou, S | 1 |
| Ahmimech, J | 1 |
| Abboud, H | 1 |
| Boutarbouch, M | 1 |
| El Hassan, A | 1 |
| Berraho, A | 1 |
| Bali, B | 1 |
| Najjar, M | 1 |
| Garcia, HH | 6 |
| Lescano, AG | 1 |
| Gonzales, I | 1 |
| Bustos, JA | 2 |
| Pretell, EJ | 3 |
| Horton, J | 4 |
| Saavedra, H | 1 |
| Gonzalez, AE | 3 |
| Gilman, RH | 4 |
| Chaoshuang, L | 1 |
| Zhixin, Z | 1 |
| Xiaohong, W | 1 |
| Zhanlian, H | 1 |
| Zhiliang, G | 1 |
| Okuyama, H | 1 |
| Kanamori, M | 1 |
| Watanabe, M | 1 |
| Kumabe, T | 1 |
| Tominaga, T | 1 |
| Coulibaly, B | 1 |
| Gautier, G | 1 |
| Fuentes, S | 1 |
| Ranque, S | 1 |
| Bouvier, C | 1 |
| Burneo, JG | 1 |
| Plener, I | 1 |
| Ramaratnam, S | 2 |
| Sharma, T | 1 |
| Khosla, VK | 1 |
| Brar, R | 1 |
| Nayil, K | 1 |
| Ramzan, A | 1 |
| Jain, A | 1 |
| Altas, M | 1 |
| Aras, M | 1 |
| Serarslan, Y | 1 |
| Davran, R | 1 |
| Evirgen, O | 1 |
| Yilmaz, N | 1 |
| Sundar, U | 1 |
| Chawla, V | 1 |
| Lakkas, Y | 1 |
| Shrivastava, M | 1 |
| Asole, D | 1 |
| Vaidy, M | 1 |
| Khan, FY | 1 |
| Imam, YZ | 1 |
| Kamel, H | 1 |
| Shafaee, M | 1 |
| Takayanagui, OM | 5 |
| Odashima, NS | 1 |
| Bonato, PS | 3 |
| Lima, JE | 1 |
| Lanchote, VL | 3 |
| Cece, H | 1 |
| Sogut, O | 1 |
| Kaya, H | 1 |
| Işıkay, S | 1 |
| Yılmaz, K | 1 |
| Ölmez, A | 1 |
| Ozdemir, NG | 1 |
| Kurt, A | 1 |
| Binici, DN | 1 |
| Ozsoy, KM | 1 |
| Verma, R | 1 |
| Jaiswal, A | 1 |
| Nowak, DA | 1 |
| Lücking, MO | 1 |
| Böhmer, RH | 1 |
| Schreiner, R | 1 |
| Fuchs, HH | 1 |
| Flügel, KA | 1 |
| Dreossi, SA | 1 |
| Maguire, JH | 1 |
| Martinez, SM | 1 |
| Moulton, LH | 1 |
| Del Brutto, OH | 13 |
| Herrera, G | 2 |
| Evans, CA | 1 |
| Sotelo, J | 15 |
| Sabbatani, S | 1 |
| Fasulo, G | 1 |
| Chiodo, F | 1 |
| Singhi, P | 3 |
| Jain, V | 1 |
| Khandelwal, N | 3 |
| Karabay, O | 1 |
| Onen, A | 1 |
| Yildiz, F | 1 |
| Yilmaz, E | 1 |
| Erdal, CA | 1 |
| Sanli, A | 1 |
| Kilci, G | 1 |
| Algin, I | 1 |
| Itil, O | 1 |
| Açikel, U | 1 |
| Im, SH | 1 |
| Park, SH | 1 |
| Oh, DH | 1 |
| Kang, BS | 1 |
| Kwon, OK | 1 |
| Oh, CW | 1 |
| Beskonakli, E | 1 |
| Solaroglu, I | 1 |
| Tun, K | 1 |
| Albayrak, L | 1 |
| Llanos-Zavalaga, F | 1 |
| Yilmaz, Y | 1 |
| Kösem, M | 1 |
| Ceylan, K | 1 |
| Köseoglu, B | 1 |
| Yalçinkaya, I | 1 |
| Arslan, H | 1 |
| Güneş, M | 1 |
| Söylemez, O | 1 |
| Salinas, R | 2 |
| Prasad, K | 2 |
| Isik, N | 1 |
| Silav, G | 1 |
| Cerçi, A | 1 |
| Karabagli, P | 1 |
| Elmaci, I | 1 |
| Kalelioglu, M | 1 |
| Mahajan, V | 1 |
| Khandelwal, NK | 1 |
| Rajshekhar, V | 4 |
| Ntusi, NA | 1 |
| Horsfall, C | 1 |
| Carpio, A | 2 |
| Santillán, F | 1 |
| León, P | 1 |
| Flores, C | 1 |
| Hauser, WA | 2 |
| Gunnarsson, G | 1 |
| Hurlbut, D | 1 |
| DeGirolami, PC | 1 |
| Federman, M | 1 |
| Wanke, C | 1 |
| Quintero, LA | 1 |
| Schmidt, DK | 1 |
| Jordaan, HF | 1 |
| Schneider, JW | 1 |
| Cilliers, J | 1 |
| Garg, RK | 2 |
| Ghariani, S | 1 |
| Gille, M | 1 |
| Matthijs, P | 1 |
| Delbecq, J | 1 |
| Depré, A | 1 |
| Agarwal, AK | 1 |
| Dudeja, RK | 1 |
| Chandra, S | 1 |
| Sanchetee, PC | 1 |
| Venkataraman, S | 1 |
| Dhamija, RM | 1 |
| Roy, AK | 1 |
| Chagnon, A | 2 |
| Galzin, M | 1 |
| de Jaureguiberry, JP | 1 |
| Boyer, B | 1 |
| Paris, JF | 2 |
| Marlier, S | 1 |
| Carli, P | 2 |
| Monteiro, L | 1 |
| Almeida-Pinto, J | 1 |
| Stocker, A | 1 |
| Sampaio-Silva, M | 1 |
| Qui, MD | 1 |
| Wen, LC | 1 |
| Cheng, DJ | 1 |
| Chotmongkol, V | 3 |
| Bauer, TM | 1 |
| Brühwiler, J | 1 |
| Aschwanden, M | 1 |
| Wagner, S | 1 |
| Schwander, J | 1 |
| Suri, W | 1 |
| Kalra, V | 1 |
| Sánchez, M | 3 |
| Suástegui, R | 1 |
| González-Esquivel, D | 1 |
| Jung, H | 4 |
| Dharnidharka, VR | 1 |
| Noboa, C | 1 |
| Moskopp, D | 1 |
| Lotterer, E | 1 |
| Cruz, I | 2 |
| Cruz, ME | 1 |
| Carrasco, F | 1 |
| Agapejev, S | 1 |
| Da Silva, MD | 1 |
| Ueda, AK | 1 |
| Ciurea, AV | 1 |
| Vasilescu, G | 1 |
| Nuteanu, L | 1 |
| Carp, N | 1 |
| Kar, AM | 1 |
| Jain, S | 1 |
| Maddalena, G | 1 |
| Nozzoli, C | 1 |
| Passarella, B | 1 |
| Whitefield, L | 1 |
| Crowston, JG | 1 |
| Davey, C | 1 |
| Alla, P | 1 |
| Marques, MP | 1 |
| Zaiman, H | 1 |
| Martinez, M | 1 |
| Altamirano, J | 1 |
| Cuba, JM | 1 |
| Rios-Saavedra, N | 1 |
| Verastegui, M | 1 |
| Boero, J | 1 |
| Proaño, JV | 2 |
| Madrazo, I | 2 |
| García, L | 1 |
| García-Torres, E | 1 |
| Correa, D | 1 |
| Chandy, MJ | 1 |
| Struillou, L | 1 |
| Rabaud, C | 1 |
| Bischoff, N | 1 |
| Preiss, MA | 1 |
| May, T | 1 |
| Canton, P | 1 |
| Manzano-Blanco, S | 1 |
| Gutiérrez-Solana, LG | 1 |
| García-Peñas, JJ | 1 |
| García-Guzmán, P | 1 |
| Ruiz-Falcó, ML | 1 |
| Ko, DY | 1 |
| Chang, GY | 1 |
| Schmid, M | 1 |
| Pendl, G | 1 |
| Samonigg, H | 1 |
| Ranner, G | 1 |
| Eustacchio, S | 1 |
| Reisinger, EC | 1 |
| Escobar, A | 1 |
| Yüceer, N | 2 |
| Güven, MB | 1 |
| Yilmaz, H | 1 |
| Wang, S | 1 |
| Yu, X | 1 |
| Wu, J | 1 |
| Gökalp, HZ | 1 |
| Rajadhyaksha, S | 1 |
| Shah, KN | 1 |
| Kanhere, S | 1 |
| Naik, N | 1 |
| Mehta, R | 1 |
| Ray, M | 1 |
| Singhi, S | 1 |
| Suarez, VR | 1 |
| Iannucci, TA | 1 |
| Huang, PP | 1 |
| Choudhri, HF | 1 |
| Jallo, G | 1 |
| Miller, DC | 1 |
| Sugiyama, M | 1 |
| Okada, T | 1 |
| Higuchi, H | 1 |
| Yabe, Y | 1 |
| Kobayashi, N | 1 |
| Teramoto, A | 1 |
| Khaldi, M | 1 |
| Mohamed, S | 1 |
| Kallel, J | 1 |
| Khouja, N | 1 |
| Baranwal, AK | 1 |
| Singhi, PD | 1 |
| Singhi, SC | 1 |
| Avelar, F | 1 |
| López-Félix, B | 1 |
| Díaz, G | 1 |
| Grijalva, I | 1 |
| Fournier, S | 1 |
| Liguory, O | 1 |
| Sarfati, C | 1 |
| David-Ouaknine, F | 1 |
| Derouin, F | 1 |
| Decazes, JM | 1 |
| Molina, JM | 1 |
| Lowalekar, KB | 1 |
| Singounas, EG | 1 |
| Leventis, AS | 1 |
| Sakas, DE | 1 |
| Hadley, DM | 1 |
| Lampadarios, DA | 1 |
| Karvounis, PC | 1 |
| Vazquez, V | 1 |
| Silarugs, S | 1 |
| Jardim, E | 1 |
| Rivierez, M | 1 |
| el-Azhari, A | 1 |
| el Tantaoui, M | 1 |
| Alaoui, M | 1 |
| Aguirre, R | 1 |
| Díaz-Calderón, E | 1 |
| Alarcón, TA | 1 |
| Cohen, L | 1 |
| Belec, L | 1 |
| Sanson, M | 1 |
| Pierrot-Deseilligny, C | 1 |
| Signoret, JL | 1 |
| Hurtado, M | 2 |
| Medina, MT | 2 |
| Puri, V | 1 |
| Sharma, DK | 1 |
| Kumar, S | 1 |
| Choudhury, V | 1 |
| Gupta, RK | 1 |
| Khalil, A | 1 |
| Cruz, M | 1 |
| Davis, LE | 1 |
| Kornfeld, M | 1 |
| Chong, MS | 1 |
| Hawkins, CP | 1 |
| Cook, GC | 1 |
| Hawkes, CH | 1 |
| Kocen, RS | 1 |
| Santoyo, H | 1 |
| Corona, R | 1 |
| Mehndiratta, MM | 1 |
| Gupta, M | 1 |
| Jagota, SC | 1 |
| Penagos, P | 5 |
| Escobedo, F | 5 |
| Torres, B | 1 |
| Rodriguez-Carbajal, J | 1 |
| Rubio-Donnadieu, F | 1 |
| Gupta, R | 1 |
| Yadav, NV | 1 |
| Rodríguez, J | 2 |
| del Bruto, O | 1 |
| Alarcón, F | 1 |
| Escalante, L | 1 |
| Dueñas, G | 1 |
| Montalvo, M | 1 |
| Román, M | 1 |
| Quintero-Rodriguez, E | 1 |
| Todorov, T | 1 |
| Vutova, K | 1 |
| Petkov, D | 1 |
| Balkanski, G | 1 |
| Hwang, KP | 1 |
| Chen, ER | 1 |
| Xiao, ZX | 1 |
| Zhao, CY | 1 |
| Liu, YP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole[NCT00441285] | Phase 2/Phase 3 | 156 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients whose 6 month MR does not show viable parasites anymore (NCT00441285)
Timeframe: Day 180
| Intervention | participants (Number) |
|---|---|
| Phase III Trial - ABZ+PZQ | 25 |
| Phase III Trial - Increased ABZ | 19 |
| Phase III Trial - Standard ABZ | 15 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Albendazole + Praziquantel | 4925.3 |
| Albendazole + Placebo | 2969.6 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1
| Intervention | ng*h/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1412.2 |
| Albendazole + Placebo | 1111 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Carbamazepine | 240.2 |
| Phenytoin | 550.1 |
Highest serum level of Albendazole measured from all level assessments in the curve. (NCT00441285)
Timeframe: Treatment day 1 and Treatment days 10-11
| Intervention | ng/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1293.9 |
| Albendazole + Placebo | 2232.8 |
- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy. (NCT00441285)
Timeframe: 90 days post tx
| Intervention | Events (Number) |
|---|---|
| Albendazole + Praziquantel | 0 |
| Albendazole + Placebo | 0 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1
| Intervention | ng*h / mL (Mean) | |
|---|---|---|
| Carbamazepine (n=8) | Phenytoin (n=8) | |
| Albendazole + Praziquantel | 548.3 | 923.7 |
18 reviews available for albendazole and Brain Diseases
| Article | Year |
|---|---|
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Bias; Brain Diseases; Child; Humans; Neurocysticercosis; Pl | 2021 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neurocysticercosis; Praziqua | 2010 |
Anthelmintics for people with neurocysticercosis.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neu | 2010 |
Medical management of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain Diseases; Humans; Life Cycle Stages; Magnetic Resonance I | 2011 |
[Brain cysticercosis: review and case report].
Topics: Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Brain Edema; Diagnostic Errors; Emigrati | 2003 |
WITHDRAWN: Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2007 |
Cerebral alveolar echinococcosis. A case report with MRI and review of the literature.
Topics: Albendazole; Animals; Antiprotozoal Agents; Brain Diseases; Echinococcosis; Echinococcus multilocula | 2007 |
Multiorgan microsporidiosis: report of five cases and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Albendazole; Animals; Anthelmintics; Biliary Tract Dis | 1995 |
[Cerebral cysticercosis treated by albendazole: development of cerebral magnetic resonance imaging].
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Epilepsy, Tonic-Clonic; Follow-Up Studies; Humans | 1994 |
Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients.
Topics: Adolescent; Adult; Albendazole; Animals; Antibodies, Helminth; Brain Diseases; Cerebrospinal Fluid S | 1993 |
Treatment of brain cysticercosis.
Topics: Albendazole; Anthelmintics; Anti-Inflammatory Agents; Brain Diseases; Cysticercosis; Dexamethasone; | 1997 |
Pharmacokinetic optimisation of the treatment of neurocysticercosis.
Topics: Absorption; Albendazole; Animals; Anthelmintics; Biological Availability; Brain Diseases; Cysticerco | 1998 |
Cysticercosis and epilepsy: a critical review.
Topics: Albendazole; Anthelmintics; Antiplatyhelmintic Agents; Brain; Brain Diseases; Clinical Trials as Top | 1998 |
Multiple hydatid cysts of the brain: a case report and review of the literature.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Combined Modality Therapy; Echinococcosis; Humans | 1998 |
Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2000 |
Disseminated infection due to Encephalitozoon cuniculi in a patient with AIDS: case report and review.
Topics: AIDS-Related Opportunistic Infections; Albendazole; Animals; Antiprotozoal Agents; Brain Diseases; D | 2000 |
Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature.
Topics: Adult; Albendazole; Brain Diseases; Echinococcosis; Female; Humans; Tomography, X-Ray Computed | 1992 |
Neurocysticercosis: neurologic, pathogenic, diagnostic and therapeutic aspects.
Topics: Albendazole; Animals; Brain Diseases; Cysticercosis; Humans; Magnetic Resonance Imaging; Meninges; P | 1991 |
19 trials available for albendazole and Brain Diseases
| Article | Year |
|---|---|
Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anticestodal Agents; Brain Diseases; Female; Humans; Male; | 2016 |
A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants | 2004 |
Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis.
Topics: Adolescent; Albendazole; Anticestodal Agents; Brain; Brain Diseases; Child; Child, Preschool; Drug T | 2004 |
Is the course of neurocysticercosis modified by treatment with antihelminthic agents?
Topics: Adult; Aged; Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Drug Therapy, Combination; F | 1995 |
Albendazole therapy for neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Child; Cysticercosis; Female; Follow-Up Studies; Hum | 1994 |
Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures.
Topics: Adolescent; Adult; Albendazole; Animals; Brain Diseases; Cysticercosis; Cysticercus; Female; Granulo | 1993 |
Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Administration Schedule; Female; | 1993 |
Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Brain Diseases; Cimetidine; | 1997 |
Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Double-Blind Method; Electroenceph | 1997 |
Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle.
Topics: Adult; Albendazole; Anthelmintics; Antiplatyhelmintic Agents; Brain Diseases; Cerebral Ventricles; C | 1997 |
Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures.
Topics: Albendazole; Anthelmintics; Brain Diseases; Clinical Protocols; Cysticercosis; Diagnosis, Differenti | 1997 |
Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas?
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Antitubercular Agents; Brain Diseases; Chil | 1999 |
Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Child, Preschool; Diagnosis, Differential; Female | 2000 |
Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up.
Topics: Albendazole; Anticonvulsants; Brain Diseases; Child; Double-Blind Method; Drug Therapy, Combination; | 2001 |
Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anticestodal Agents; Brain Diseases; Dexame | 2001 |
Therapy for neurocysticercosis. Comparison between albendazole and praziquantel.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Cerebrospinal Fluid; Child; Child, Preschool; Cystic | 1992 |
Clinical evaluation of albendazole and praziquantel in the treatment of cerebral cysticercosis.
Topics: Adult; Albendazole; Brain; Brain Diseases; Cysticercosis; Electroencephalography; Female; Follow-Up | 1991 |
Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Brain Diseases; Cysticercosis; Drug Administration Schedule; F | 1990 |
Albendazole therapy for human neurocysticercosis, a controlled study with computerized tomography and magnetic resonance.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Child; Cysticercosis; Female; Humans; Magnetic Reson | 1989 |
97 other studies available for albendazole and Brain Diseases
| Article | Year |
|---|---|
Hydatid brain cyst: A delayed diagnosis in a rural setting during COVID-19.
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Child; COVID-19; Delayed Diagnosis; Echinococcosis | 2021 |
Mesenchymal stem cells combined with albendazole as a novel therapeutic approach for experimental neurotoxocariasis.
Topics: Albendazole; Animals; Antinematodal Agents; Brain Diseases; Disease Models, Animal; Mesenchymal Stem | 2020 |
Health Care Without Borders: A Case Report of an Immigrant Child Who Lost His Voice.
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Brain; Brain Diseases; Emigrants and Immigr | 2019 |
Giant Primary Intracranial Hydatid Cyst in Child with Hemiparesis.
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Child; Craniotomy; Echinococcosis; Female; Humans; | 2019 |
Intracranial hydatid cyst.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Echinococcosis; Frontal Lobe; Humans; Male; Treat | 2014 |
Left ventricular endocardial ecchinococcosis associated with multiple intracranial hydatid cysts.
Topics: Adolescent; Albendazole; Anticestodal Agents; Brain Diseases; Cardiac Surgical Procedures; Cardiopul | 2013 |
Primary intracranial and spinal hydatidosis: a retrospective study of 21 cases.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Central Nervous System Cysts | 2013 |
Millairy neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child, Preschool; Drug Therapy, Combination; Humans; Mag | 2014 |
Swollen eyelid reveals multiple intracranial hydatid cysts associated with a palpebral cyst.
Topics: Albendazole; Brain Diseases; Central Nervous System Helminthiasis; Child; Cysts; Echinococcosis; Ede | 2016 |
Preoperative diagnosis of cerebral hydatid cyst and its therapeutic implications.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Craniotomy; Echinococcosis; Humans; Magnetic Reso | 2016 |
Clinical analysis of 52 cases of neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain; Brain Diseases; Child; China; Female; Humans; | 2008 |
[Multiple intracerebral enhanced lesions strongly suspected to be microsporidiosis. A case report].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Humans; Male; Microsporidiosis | 2008 |
[Degenerating neurocysticercosis cysts: differential diagnosis with cerebral metastasis].
Topics: Adrenal Cortex Hormones; Aged; Albendazole; Anthelmintics; Biopsy; Brain Diseases; Brain Neoplasms; | 2008 |
Neurocysticercosis in a patient in Canada.
Topics: Albendazole; Anti-Inflammatory Agents; Anticonvulsants; Antiprotozoal Agents; Brain; Brain Diseases; | 2009 |
Primary extradural hydatid cyst associated with nephrotic syndrome in a pediatric patient.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Echinococcosis; Female; Humans; Nephrotic Syndrom | 2010 |
Footprint in brain.
Topics: Adolescent; Albendazole; Antiprotozoal Agents; Brain Diseases; Craniotomy; Echinococcosis; Epilepsy, | 2011 |
A medically treated multiple cerebral hydatid cyst disease.
Topics: Albendazole; Anthelmintics; Brain Diseases; Echinococcosis; Humans; Male; Middle Aged; Tomography, X | 2010 |
Monocular blindness during therapy for cerebral neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Anticonvulsants; Blindness; Brain Diseases; Dexamethasone; | 2010 |
Neurocysticercosis in Qatari patients: case reports.
Topics: Adolescent; Albendazole; Animals; Anti-Inflammatory Agents; Anticestodal Agents; Anticonvulsants; Br | 2011 |
Primary giant intracranial extracerebral hydatid disease in a child.
Topics: Albendazole; Animals; Brain Diseases; Child; Craniotomy; Echinococcosis; Echinococcus granulosus; Fr | 2011 |
[Two cases of rare cerebral hydatid cyst].
Topics: Abducens Nerve Diseases; Adolescent; Albendazole; Anthelmintics; Brain Diseases; Chemotherapy, Adjuv | 2012 |
Echinococcus alveolaris: presenting as a cerebral metastasis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Brain; Brain Diseases; Brain Edema; Brain Neoplasms; Dia | 2012 |
Multiple brain parenchymal neurocysticercosis with extraocular muscle cysticercosis affecting levator palpebral superioris and superior rectus complex: an unusual association.
Topics: Albendazole; Anti-Inflammatory Agents; Anticestodal Agents; Blepharoptosis; Brain Diseases; Child; C | 2013 |
[Isolated intracerebral cystic echinococcosis. Unusual presentation of a rare disease].
Topics: Albendazole; Anthelmintics; Brain; Brain Diseases; Diagnosis, Differential; Echinococcosis; Female; | 2002 |
Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Female; Humans; Male; Middle Aged; Neurocysticerc | 2002 |
Tapeworms and seizures--treatment and prevention.
Topics: Albendazole; Animals; Anticestodal Agents; Brain Diseases; Developing Countries; Humans; Life Cycle | 2004 |
Neurocysticercosis--is the elimination of parasites beneficial?
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Follow-Up Studies; Granuloma; Humans; Neurocystice | 2004 |
The case of a cyst hydatid localized within the interatrial septum.
Topics: Adult; Albendazole; Anticestodal Agents; Brain Diseases; Cardiac Surgical Procedures; Cardiomyopathi | 2004 |
Subdural cysticercosis mimicking a chronic subdural hematoma. Case illustration.
Topics: Aged; Aged, 80 and over; Albendazole; Brain Diseases; Diagnosis, Differential; Hematoma, Subdural, C | 2005 |
Primary intracranial hydatid cyst in the interpeduncular cistern.
Topics: Adult; Albendazole; Brain Diseases; Central Nervous System Parasitic Infections; Combined Modality T | 2005 |
Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain Diseases; Drug Administration Schedule; Female; | 2006 |
Our experience in eight cases with urinary hydatid disease: a series of 372 cases held in nine different clinics.
Topics: Adult; Albendazole; Antiprotozoal Agents; Brain Diseases; Child; Echinococcosis; Humans; Retrospecti | 2006 |
Sudden-onset ptosis caused by midbrain neurocysticercosis in 2 children.
Topics: Acute Disease; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Blepharoptosis; Brain Diseases; | 2008 |
Albendazole therapy in patients with solitary cerebral cysticercus granuloma. Is it effective?
Topics: Albendazole; Anthelmintics; Brain Diseases; Granuloma; Humans; Neurocysticercosis; Research Design | 2008 |
Severe disseminated hydatid disease successfully treated medically with prolonged administration of albendazole.
Topics: Administration, Oral; Adult; Albendazole; Anthelmintics; Brain; Brain Diseases; Central Nervous Syst | 2008 |
Cysticercosis mimicking brain tumor: the role of albendazole as a diagnostic tool.
Topics: Albendazole; Anthelmintics; Brain Diseases; Brain Neoplasms; Cysticercosis; Diagnosis, Differential; | 1995 |
Cerebral and subcutaneous cysticercosis treated with albendazole.
Topics: Adult; Albendazole; Anthelmintics; Antiparasitic Agents; Brain Diseases; Cysticercosis; Humans; Male | 1995 |
Solitary cysticercus granulomas.
Topics: Albendazole; Animals; Brain Diseases; Cysticercosis; Granuloma; Humans; Seizures; Tomography, X-Ray | 1995 |
Advances in treatment of neurocysticercosis.
Topics: Albendazole; Brain Diseases; Controlled Clinical Trials as Topic; Cysticercosis; Drug Administration | 1994 |
[Prolonged treatment of recurrent neurocysticercosis using sequential doses of albendazole and praziquantel].
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Administration Schedule; Drug Therapy, Combi | 1994 |
Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Child; Cysticercosis; Epilepsy; Female; Humans; Male | 1994 |
Brain alveococcosis. Therapeutic experience in 14 cases.
Topics: Adult; Aged; Albendazole; Brain; Brain Diseases; Echinococcosis; Female; Humans; Male; Middle Aged; | 1994 |
Treatment of neurocysticercosis with a two week course of albendazole.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Administration Schedule; Epileps | 1993 |
[Neurocysticercosis].
Topics: Albendazole; Animals; Antibodies, Helminth; Brain; Brain Diseases; Croatia; Cysticercosis; Diagnosis | 1994 |
Neurocysticercosis.
Topics: Albendazole; Brain Diseases; Child; Cysticercosis; Humans; India; Magnetic Resonance Imaging; Tomogr | 1994 |
Case 8-1993: cysticercosis.
Topics: Albendazole; Brain Diseases; Cysticercosis; Humans; Praziquantel; Subarachnoid Space | 1993 |
The use of albendazole in patients with single lesions enhanced on contrast CT.
Topics: Albendazole; Brain Diseases; Brain Neoplasms; Cysticercosis; Humans; Tomography, X-Ray Computed | 1993 |
Albendazole--newer therapy for neurocysticercosis.
Topics: Albendazole; Brain Diseases; Cysticercosis; Dexamethasone; Drug Therapy, Combination; Humans | 1993 |
Albendazole therapy for giant subarachnoid cysticerci.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Dexamethasone; Female; Humans; Subarachnoid Space | 1993 |
Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst.
Topics: Albendazole; Blood-Brain Barrier; Brain Diseases; Cerebrospinal Fluid Shunts; Child; Combined Modali | 1993 |
Neurocysticercosis: optimal dose treatment with albendazole.
Topics: Adult; Albendazole; Analysis of Variance; Anthelmintics; Brain Diseases; Cysticercosis; Dose-Respons | 1995 |
Severe forms of neurocysticercosis: treatment with albendazole.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain Diseases; Chlorpheniramine; Cysticercosis; Fema | 1996 |
Cerebral hydatid cyst in children. Experience of 27 cases.
Topics: Adolescent; Albendazole; Anthelmintics; Brain Diseases; Cerebral Cortex; Child; Child, Preschool; Ec | 1995 |
Failure of albendazole therapy in two common types of parenchymal neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Brain; Brain Diseases; Cysticercosis; Humans; Male; Tomography, X | 1995 |
Neurocysticercosis treated with albendazole long term follow-up of a case.
Topics: Albendazole; Brain Diseases; Cysticercosis; Humans; Magnetic Resonance Imaging; Male; Middle Aged; T | 1995 |
Cavernous sinus syndrome associated with neurocysticercosis.
Topics: Adult; Albendazole; Brain Diseases; Cavernous Sinus; Cysticercosis; Frontal Lobe; Humans; Male; Pred | 1996 |
[Results of sequential prolonged courses of albendazole and praziquantel in recurrent neurocysticercosis].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Drug Therapy, Combination; Humans; | 1996 |
Presentation of parasites and the radiology of parasitic diseases.
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Echinococcosis; Fatal Outcome; Female; Humans | 1997 |
[Complications of cardiac hydatid cyst. 2 cases].
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain Diseases; Cardiac Tamponade; Cardiomyopathies; | 1997 |
[A case of mixed (parenchymatous meningo-basal) neurocysticercosis].
Topics: Albendazole; Anthelmintics; Anti-Inflammatory Agents; Brain Diseases; Calcinosis; Child; Cysticercos | 1997 |
[Neurocysticercosis in children: clinical and radiological analysis and prognostic factors in 54 patients].
Topics: Adolescent; Albendazole; Anthelmintics; Anticonvulsants; Brain; Brain Diseases; Carbamazepine; Child | 1997 |
Albendazole therapy for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Humans | 1998 |
Albendazole therapy for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Humans | 1998 |
Gamma knife radiosurgery and albendazole for cerebral alveolar hydatid disease.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Combined Modality Therapy; Echinococcosis; Female | 1998 |
[Delayed encephalopathy in childhood caused by anthelmintics].
Topics: Albendazole; Anthelmintics; Brain Diseases; Child; Child, Preschool; Humans; Male | 1997 |
Periventricular hydatid cyst.
Topics: Albendazole; Animals; Anthelmintics; Brain Diseases; Cerebral Ventricles; Cerebral Ventriculography; | 1998 |
Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Perú.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Car | 1999 |
Neurocysticercosis in pregnancy: a case initially diagnosed as eclampsia.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cerebral Ventricles; Diagnosis, Differential; Ecl | 1999 |
Inflammatory aneurysm and neurocysticercosis: further evidence for a causal relationship? Case report.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Cerebral Angiography; Humans; Inflammation; Intra | 2000 |
[A case of neurocysticercosis presenting as focal seizure].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Combined Modality Therapy; Humans; Male; Neurocys | 2000 |
Brain hydatidosis: report on 117 cases.
Topics: Adolescent; Albendazole; Brain Diseases; Central Nervous System Helminthiasis; Child; Child, Prescho | 2000 |
Cerebral cysticercus granuloma associated with a subdural effusion.
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Epilepsy; Female; Granuloma; Humans; Magnetic Res | 2001 |
Albendazole therapy in ring lesions of neurocysticercosis.
Topics: Adolescent; Albendazole; Brain Diseases; Child; Cysticercosis; Diagnosis, Differential; Humans; Male | 1992 |
Albendazole treatment of neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Brain Diseases; Cysticercosis; Female; Follow-Up Studies; Humans; Ma | 1992 |
The course of seizures after treatment for cerebral cysticercosis.
Topics: Adult; Albendazole; Brain; Brain Diseases; Cysticercosis; Epilepsy; Female; Follow-Up Studies; Human | 1992 |
Transient paralytic attacks with cerebral cysticercosis.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Therapy, Combination; Epilepsy, Tonic-Clonic | 1992 |
[Hydatid cyst of the cavernous sinus. A case].
Topics: Adult; Albendazole; Brain Diseases; Cavernous Sinus; Echinococcosis; Female; Humans; Magnetic Resona | 1992 |
Albendazole therapy for giant subarachnoid cysticerci.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Humans; Male; Middle Aged; Subarachnoid Space; To | 1992 |
[Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis].
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Resistance; Drug Therapy, Combination; Follo | 1992 |
Clinical pharmacokinetics of albendazole in patients with brain cysticercosis.
Topics: Administration, Oral; Adult; Aged; Albendazole; Anthelmintics; Brain Diseases; Cysticercosis; Female | 1992 |
Neurocysticercosis in children.
Topics: Adolescent; Albendazole; Brain Diseases; Child; Child, Preschool; Cysticercosis; Drug Therapy, Combi | 1991 |
A resistant case of neurocystercercosis.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Resistance; Drug Therapy, Combination; Femal | 1991 |
Total recovery of visual function after treatment for cerebral cysticercosis.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Female; Humans; Vision, Ocular; Visual Acuity; Vi | 1991 |
Neurocysticercosis.
Topics: Albendazole; Brain Diseases; Cysticercosis; Humans; Praziquantel | 1990 |
Neurocysticercosis.
Topics: Albendazole; Brain Diseases; Cysticercosis; Drug Administration Schedule; Humans; Praziquantel | 1990 |
Albendazole therapy for neurocysticercosis.
Topics: Albendazole; Brain Diseases; Cysticercosis; Humans; Radiography | 1990 |
Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis.
Topics: Adolescent; Adult; Age Factors; Aged; Albendazole; Brain Diseases; Child; Cysticercosis; Female; Hum | 1990 |
Albendazole therapy for subarachnoid and ventricular cysticercosis. Case report.
Topics: Adult; Albendazole; Brain Diseases; Cerebral Ventricles; Cerebral Ventriculography; Cysticercosis; F | 1990 |
Failure of praziquantel and albendazole in neurocysticercosis.
Topics: Adult; Albendazole; Brain Diseases; Cysticercosis; Drug Therapy, Combination; Follow-Up Studies; Hum | 1990 |
Neurocysticercosis. Short course of treatment with albendazole.
Topics: Adolescent; Adult; Aged; Albendazole; Brain Diseases; Cysticercosis; Female; Humans; Male; Middle Ag | 1989 |
Praziquantel vs. albendazol for cysticercosis.
Topics: Albendazole; Anthelmintics; Benzimidazoles; Brain Diseases; Cysticercosis; Humans; Mexico; Praziquan | 1988 |
Albendazole treatment of multiple cerebral hydatid cysts: case report.
Topics: Albendazole; Anthelmintics; Benzimidazoles; Brain Diseases; Echinococcosis; Humans; Male; Middle Age | 1988 |
Short course of albendazole therapy for neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Benzimidazoles; Brain; Brain Diseases; Cysticercosis; Female; Hem | 1988 |
Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial.
Topics: Adult; Albendazole; Benzimidazoles; Brain Diseases; Cysticercosis; Female; Humans; Male; Middle Aged | 1988 |
Larvicidal effect of albendazole against Angiostrongylus cantonensis in mice.
Topics: Albendazole; Angiostrongylus; Animals; Anthelmintics; Benzimidazoles; Brain Diseases; Dose-Response | 1988 |
[Albendazole treatment in cerebral cysticercosis].
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Benzimidazoles; Brain Diseases; Child; Cysticer | 1986 |
Albendazole therapy for neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Benzimidazoles; Brain Diseases; Cysticercosis; Female; Follow-Up | 1987 |